{"id":"NCT00658021","sponsor":"AstraZeneca","briefTitle":"Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes","officialTitle":"Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-05-30","primaryCompletion":"2019-04-18","completion":"2020-04-01","firstPosted":"2008-04-14","resultsPosted":"2020-12-01","lastUpdate":"2020-12-01"},"enrollment":122,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Exenatide","otherNames":[]},{"type":"DRUG","name":"Exenatide","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Exenatide 5 µg","type":"EXPERIMENTAL"},{"label":"Exenatide 10 µg","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study is to test the hypothesis that glycemic control, as measured by change in hemoglobin A1c (HbA1c) from baseline to endpoint, with exenatide is superior to that of placebo after 28 weeks of treatment in adolescent patients with type 2 diabetes who are naïve to antidiabetes agents, or patients who are being treated with metformin, an SU, or a combination of metformin and an SU","primaryOutcome":{"measure":"Adjusted Change From Baseline in Glycated Hemoglobin A1c (HbA1c) at Week 28","timeFrame":"Baseline (Day 1) and Week 28","effectByArm":[{"arm":"Total Exenatide Twice Daily (EBID)","deltaMin":0.11,"sd":0.215},{"arm":"Placebo","deltaMin":0.38,"sd":0.293}],"pValues":[{"comp":"OG000 vs OG001","p":"0.444"}]},"eligibility":{"minAge":"10 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":8},"locations":{"siteCount":53,"countries":["United States","Brazil","India","Mexico","Philippines","Russia","South Africa","South Korea"]},"refs":{"pmids":[],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5550C00002&amp;attachmentIdentifier=305e146c-5f7f-45a2-85e8-a10dafda43fb&amp;fileName=D5550C00002_CSP_redacted.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5550C00002&amp;attachmentIdentifier=6cfc1d5f-a256-4d8b-8b54-6944c1993205&amp;fileName=D5550C00002_Statistical_Analysis_Plan.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":41},"commonTop":["Headache","Nausea","Vomiting","Nasopharyngitis","Upper respiratory tract infection"]}}